Ando Katsuyuki, Fujita Toshiro
Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Diabetes Obes Metab. 2006 Jul;8(4):396-403. doi: 10.1111/j.1463-1326.2005.00526.x.
Diabetes, which is frequently associated with hypertension, accelerates the development of hypertension-induced cardiovascular disease. Thus, the prevention of diabetes is important in the management of hypertension. Recent clinical megastudies have suggested that the blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibits new onset of diabetes. Thus, the agents to inhibit the RAS should be beneficial for glucose metabolism. However, the cardiovascular protective effects of ACE inhibitors and ARBs are not always superior to other classes of drugs. Further long-term clinical trials are necessary to clarify the anti-diabetic effect of the RAS-inhibiting agents.
糖尿病常与高血压相关，会加速高血压所致心血管疾病的发展。因此，预防糖尿病在高血压管理中很重要。近期的临床大型研究表明，血管紧张素转换酶（ACE）抑制剂和血管紧张素II受体阻滞剂（ARB）对肾素-血管紧张素系统（RAS）的阻断作用可抑制新发糖尿病。因此，抑制RAS的药物应对葡萄糖代谢有益。然而，ACE抑制剂和ARB的心血管保护作用并不总是优于其他类药物。有必要进行进一步的长期临床试验，以阐明RAS抑制药物的抗糖尿病作用。
